What Oncode Oncology Bridge Fund does

Oncode Oncology Bridge Fund is an early-stage oncology investment vehicle operated under Stichting Oncode Institute, a Dutch non-profit foundation headquartered in Utrecht. Its functional purpose is to provide bridge financing to promising cancer research projects that fall into the so-called "valley of death"—the stage where scientific breakthroughs are too early for traditional venture capital or government grants but too late for academic funding. The fund invests equity into oncology biotech and life-sciences companies emerging from the Oncode Institute's research network, with realized returns expected through exits or follow-on rounds.

The Bridge Fund's core product surface comprises two successive vehicles: the original Oncology Bridge Fund launched in 2022, and Oncology Bridge Fund II launched in 2026 in partnership with Ligase BioPartners to scale the proven investment model. Co-financing is provided by the Oncode Accelerator Foundation and the parent Oncode Institute, leveraging philanthropic and institutional capital to de-risk early-stage oncology bets. Distribution is institutional and partnership-driven, with no public marketing or retail channel.

The fund is structurally embedded in a Dutch oncology research ecosystem spanning 750+ researchers across 13 partner institutes, anchored by anchor funders KWF Dutch Cancer Society, Health~Holland, ZonMw, and Dutch government ministries. In July 2026, the Oncode Impact Foundation was launched as a joint initiative to bring philanthropic capital into the same funding gap. The underlying research pipeline employs AI, organoid models, patient material, and clinical data to evaluate preclinical candidates, although the fund itself does not develop proprietary AI products.

Name

Oncode Oncology Bridge Fund

Legal name

Stichting Oncode Institute

Website

https://oncodeinstitute.nl

Company type

Private

Founded year

2017

Operating status

Operating

Short description

Oncode Oncology Bridge Fund is a Dutch non-profit investment vehicle under Oncode Institute that provides early-stage bridge financing to oncology research projects facing the "valley of death" between discovery and commercialization, serving biotech and academic researchers across 13 Dutch partner institutes.

Ownership category

akta.pro rank

Product category

Life Sciences Venture Capital

NAICS

Funds, Trusts, and Other Financial Vehicles (525)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare Access & Life Sciences Impact Funds (FSANAJAI)

Keywords

• Oncology bridge funding
• Venture capital oncology
• Life sciences investment
• Early-stage biotech financing
• Cancer research funding

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations

Revenue model

1. Investment Returns: The fund generates returns through equity investments in oncology startups and biotech companies, providing capital to promising early-stage companies in exchange for ownership stakes, which are realized through exits or follow-on funding rounds.
2. Philanthropic Co-financing: The fund co-finances promising oncology projects with Oncode Accelerator and Oncode Institute, leveraging philanthropic resources alongside traditional investment to bridge funding gaps in early drug development stages.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

The Oncode Oncology Bridge Fund is an oncology-focused investment fund that provides early-stage bridge financing to help create and grow new oncology enterprises. It invests in biotech companies and research projects developing cancer treatments, addressing the 'valley of death' funding gap between scientific discovery and commercial development where promising breakthroughs often fail due to lack of capital. The fund operates within the Oncode Institute ecosystem and co-finances projects with Oncode Accelerator Foundation.

Product overview

The Oncology Bridge Fund (including its successor Oncology Bridge Fund II) is an oncology investment fund managed in partnership between Oncode Institute and Ligase BioPartners. The fund is designed to bridge the critical funding gap that often stalls promising cancer research during early development stages—often referred to as the 'valley of death'. The fund invests in early-stage oncology innovations, supporting research breakthroughs as they transition toward clinical applications. Oncology Bridge Fund II represents a scaled version of this proven investment model, expanding the capacity to support more oncology research projects.

Differentiator

Problem solved

Functional benefit

Brands

• Oncode Accelerator: Accelerates translation of cancer research into clinical applications
• Oncode Impact Foundation
• Oncology Bridge Fund
• Oncology Bridge Fund II

Products and services

• Oncology Bridge Fund An oncology-focused investment fund under Oncode Institute's valorization strategy, designed to support the translation of promising cancer research into clinical applications by providing bridge funding during critical early development stages. Targets biotech companies and research projects developing cancer treatments that lack access to traditional venture capital or government grants.
• Oncology Bridge Fund II A scaled oncology investment fund that provides financing for early-stage cancer research innovations, building on the proven investment model developed by Oncode Institute and Ligase BioPartners. Bridges the funding gap in oncology research and development by investing in early-stage cancer treatment companies and projects, expanding capacity beyond the original Bridge Fund.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered core and minor.

• Oncode Accelerator FoundationcoreStrategic or Co-development Partner · 2 July 2026Co-financing partner for the Oncology Bridge Fund. Oncode Accelerator Foundation provides strong scientific underpinning and co-finances promising projects in early stages of drug development, creating leverage for the fund's investments in oncology innovations.
• Ligase BioPartnerscoreStrategic or Co-development PartnerStrategic partnership to scale the proven oncology investment model with the launch of Oncology Bridge Fund II. Ligase BioPartners collaborates with Oncode Institute to identify and support promising oncology companies and accelerate the development of cancer treatments through bridge funding.
• Oncode InstitutecoreStrategic or Co-development PartnerParent organization providing scientific foundation, research network, and co-financing for the Oncology Bridge Fund. Oncode Institute connects the fund to 750+ researchers across 13 partner institutes in the Netherlands.
• Oncode Impact FoundationminorStrategic or Co-development PartnerRelated foundation launched to bridge funding gaps using philanthropy. The Impact Foundation focuses on early development, preclinical drug development, and early-phase clinical studies in oncology, complementing the Bridge Fund's investment activities.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Frazier Life Sciences: Healthcare-dedicated investment firm with significant oncology focus. Comparable as a specialist investor in private oncology companies across stages, including bridge and growth financings.
• MPM Capital: Specialist oncology-focused investment firm. Directly comparable as an oncology-dedicated capital provider underwriting early-stage cancer therapeutics, often co-investing with academic and charity-backed vehicles.
• Cancer Research Horizons: The commercialization and bridge-funding arm of Cancer Research UK. Directly comparable: a cancer-charity-backed vehicle that bridges the valley of death for oncology discoveries emerging from a national research network, investing in early-stage cancer therapeutics and diagnostics.
• Atlas Venture: US/UK-based life-sciences VC focused on company creation around early academic science. Comparable mission of bridging academic discoveries to funded biotech startups, with oncology as a major focus area.
• LSP (Life Sciences Partners): Amsterdam-based life-sciences investor with long history in European biotech. Comparable as a Dutch-anchored specialist healthcare/oncology VC that frequently co-invests in the same ecosystem of European academic spinouts.
• Forbion: Leading Dutch/European life-sciences VC firm with deep oncology focus. Comparable as a specialist oncology investor operating in the same geography and serving European biotech founders, though typically at Series A and beyond rather than bridge stage.

Broad incumbents

• Pfizer Ventures: Corporate venture arm of Pfizer with active oncology investing. Comparable as a large strategic oncology investor that often partners with or co-invests alongside specialist bridge funds like Oncode to access European academic oncology assets.
• Bridges Fund Management: UK-based specialist impact investment manager. Comparable as an established impact-investment platform that structures sustainable-investment vehicles across sectors, including health — relevant analogue for the fund's impact-investing DNA.

Others

• European Investment Fund (EIF): EU-level fund-of-funds and impact investor backing European VC funds including life-sciences. Comparable as a potential LP/anchor for European impact-investment vehicles in healthcare and biotech.
• KWF Dutch Cancer Society: Primary public funder of Dutch cancer research and a strategic partner/anchor funder of the Bridge Fund ecosystem. Comparable as a cancer-impact funding organization with overlapping mission, though operating primarily as grant-funder rather than investor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/oncodeinstitute
• LinkedInlinkedin.com/company/oncode-institute

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments5 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oncode Oncology Bridge Fund